Research Progress of Androgen in Polycystic Ovary Syndrome with Non-Alcoholic Fatty Liver Disease

doi:10.12280/gjszjk.20210022

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder in women of childbearing age, which is often accompanied by metabolic disorders such as obesity, insulin resistance, lipid metabolism disorder and so on. Non-alcoholic fatty liver disease (NAFLD) is a common chronic non-alcoholic liver disease, including non-alcoholic simple fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, liver cirrhosis and hepatocellular carcinoma. In recent years, studies have found that the incidence of NAFLD in patients with PCOS increases, and that the two often coexist. More and more studies have proposed that hyperandrogenemia (HA), one of the important pathophysiological factors of PCOS, plays an important role in the pathogenesis of PCOS-related NAFLD.

Key words: Polycystic ovary syndrome, Non-alcoholic fatty liver disease, Insulin resistance, Cytokines, Hyperandrogenemia, Inflammatory factors

PENG Yang-yang, XIE Qing-zhen. Research Progress of Androgen in Polycystic Ovary Syndrome with Non-Alcoholic Fatty Liver Disease[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(4): 328-333.

References 43

[1]	Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Hum Reprod, 2018, 33(9):1602-1618. doi: 10.1093/humrep/dey256. doi: 10.1093/humrep/dey256 URL
[2]	Chen Z, Yu Y, Cai J, et al. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease[J]. Trends Endocrinol Metab, 2019, 30(12):903-914. doi: 10.1016/j.tem.2019.08.006. doi: 10.1016/j.tem.2019.08.006 URL
[3]	Asfari MM, Sarmini MT, Baidoun F, et al. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome[J]. BMJ Open Gastroenterol, 2020, 7(1):e000352. doi: 10.1136/bmjgast-2019-000352. doi: 10.1136/bmjgast-2019-000352 URL
[4]	Brown AJ, Tendler DA, McMurray RG, et al. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings[J]. Endocr Pract, 2005, 11(5):319-324. doi: 10.4158/EP.11.5.319. doi: 10.4158/EP.11.5.319 pmid: 16191492
[5]	Paschou SA, Polyzos SA, Anagnostis P, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. Endocrine, 2020, 67(1):1-8. doi: 10.1007/s12020-019-02085-7. doi: 10.1007/s12020-019-02085-7 URL
[6]	Kim JJ, Kim D, Yim JY, et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45(11):1403-1412. doi: 10.1111/apt.14058. doi: 10.1111/apt.14058 URL
[7]	Wu J, Yao XY, Shi RX, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis[J]. Reprod Health, 2018, 15(1):77. doi: 10.1186/s12978-018-0519-2. doi: 10.1186/s12978-018-0519-2 URL
[8]	Wang X, Li Q, Pang J, et al. Associations between serum total, free and bioavailable testosterone and non-alcoholic fatty liver disease in community-dwelling middle-aged and elderly women[J]. Diabetes Metab, 2021, 47(3):101199. doi: 10.1016/j.diabet.2020. 09.007. doi: 10.1016/j.diabet.2020. 09.007 URL
[9]	Qu X, Donnelly R. Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome[J]. Int J Mol Sci, 2020, 21(21):8191. doi: 10.3390/ijms21218191. doi: 10.3390/ijms21218191 URL
[10]	Wang X, Xie J, Pang J, et al. Serum SHBG Is Associated With the Development and Regression of Nonalcoholic Fatty Liver Disease: A Prospective Study[J]. J Clin Endocrinol Metab, 2020, 105(3):dgz244. doi: 10.1210/clinem/dgz244. doi: 10.1210/clinem/dgz244
[11]	Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1):212-221. doi: 10.1016/j.jhep.2019.03.004. doi: S0168-8278(19)30140-0 pmid: 30871980
[12]	Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome[J]. Nat Med, 2019, 25(12):1894-1904. doi: 10.1038/s41591-019-0666-1. doi: 10.1038/s41591-019-0666-1 URL
[13]	Cheng YW, Chen KW, Kuo HC, et al. Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes[J]. Int J Obes(Lond), 2019, 43(12):2469-2479. doi: 10.1038/s41366-019-0431-z. doi: 10.1038/s41366-019-0431-z URL
[14]	Li T, Zhang T, Cui T, et al. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome[J]. J Steroid Biochem Mol Biol, 2020, 204:105752. doi: 10.1016/j.jsbmb.2020.105752. doi: 10.1016/j.jsbmb.2020.105752 URL
[15]	Abruzzese GA, Heber MF, Ferrer MJ, et al. Effects of in utero androgen excess and metformin treatment on hepatic functions[J]. Mol Cell Endocrinol, 2019, 491:110416. doi: 10.1016/j.mce.2019.03.006. doi: S0303-7207(19)30082-6 pmid: 30880153
[16]	Hamaguchi M, Kojima T, Ohbora A, et al. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women[J]. World J Gastroenterol, 2012, 18(3):237-243. doi: 10.3748/wjg.v18.i3.237. doi: 10.3748/wjg.v18.i3.237 URL
[17]	McKenzie J, Fisher BM, Jaap AJ, et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial[J]. Clin Endocrinol(Oxf), 2006, 65(1):40-44. doi: 10.1111/j.1365-2265.2006.02543.x. doi: 10.1111/j.1365-2265.2006.02543.x URL
[18]	Meda C, Barone M, Mitro N, et al. Hepatic ERα accounts for sex differences in the ability to cope with an excess of dietary lipids[J]. Mol Metab, 2020, 32:97-108. doi: 10.1016/j.molmet.2019.12.009. doi: 10.1016/j.molmet.2019.12.009 URL
[19]	Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis[J]. Liver Int, 2020, 40(2):355-359. doi: 10.1111/liv.14279. doi: 10.1111/liv.14279 URL
[20]	Sarkar MA, Suzuki A, Abdelmalek MF, et al. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD[J]. Clin Gastroenterol Hepatol, 2021, 19(6):1267-1274. doi: 10.1016/j.cgh.2020.09.045. doi: 10.1016/j.cgh.2020.09.045 URL
[21]	Park JM, Lee HS, Oh J, et al. Serum Testosterone Level Within Normal Range Is Positively Associated with Nonalcoholic Fatty Liver Disease in Premenopausal but Not Postmenopausal Women[J]. J Womens Health(Larchmt), 2019, 28(8):1077-1082. doi: 10.1089/jwh.2018.7263. doi: 10.1089/jwh.2018.7263
[22]	Qiu X, Wei Y, Liu C, et al. Hyperandrogen enhances apoptosis of human ovarian granulosa cells via up-regulation and demethylation of PDCD4[J]. Gynecol Endocrinol, 2020, 36(4):333-337. doi: 10.1080/09513590.2019.1653844. doi: 10.1080/09513590.2019.1653844 URL
[23]	Azhary J, Harada M, Takahashi N, et al. Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS[J]. Endocrinology, 2019, 160(1):119-132. doi: 10.1210/en.2018-00675. doi: 10.1210/en.2018-00675 URL
[24]	Kupreeva M, Diane A, Lehner R, et al. Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model[J]. Am J Physiol Endocrinol Metab, 2019, 316(1):E16-E33. doi: 10.1152/ajpendo.00018.2018. doi: 10.1152/ajpendo.00018.2018 URL
[25]	Polyzos SA, Kountouras J, Mantzoros CS, et al. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial[J]. Diabetes Obes Metab, 2017, 19(12):1805-1809. doi: 10.1111/dom.12989. doi: 10.1111/dom.12989 URL
[26]	Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet[J]. Endocrinology, 2010, 151(5):2040-2049. doi: 10.1210/en.2009-0869. doi: 10.1210/en.2009-0869 URL
[27]	Olaniyi KS, Oniyide AA, Adeyanju OA, et al. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS[J]. Toxicol Appl Pharmacol, 2021, 411:115381. doi: 10.1016/j.taap.2020.115381. doi: 10.1016/j.taap.2020.115381 URL
[28]	Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6):377-386. doi: 10.1038/s41575-019-0144-8. doi: 10.1038/s41575-019-0144-8 pmid: 31024089
[29]	Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7):908-922. doi: 10.1038/s41591-018-0104-9. doi: 10.1038/s41591-018-0104-9 pmid: 29967350
[30]	Andrisse S, Childress S, Ma Y, et al. Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms[J]. Endocrinology, 2017, 158(3):531-544. doi: 10.1210/en.2016-1553. doi: 10.1210/en.2016-1553 pmid: 27967242
[31]	Rostamtabar M, Esmaeilzadeh S, Tourani M, et al. Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome[J]. J Cell Physiol, 2021, 236(2):824-838. doi: 10.1002/jcp.29912. doi: 10.1002/jcp.29912 URL
[32]	Sarkar M, Wellons M, Cedars MI, et al. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife[J]. Am J Gastroenterol, 2017, 112(5):755-762. doi: 10.1038/ajg.2017.44. doi: 10.1038/ajg.2017.44 URL
[33]	Cox MJ, Edwards MC, Rodriguez Paris V, et al. Androgen Action in Adipose Tissue and the Brain are Key Mediators in the Development of PCOS Traits in a Mouse Model[J]. Endocrinology, 2020, 161(7):bqaa061. doi: 10.1210/endocr/bqaa061. doi: 10.1210/endocr/bqaa061
[34]	O′Reilly MW, Kempegowda P, Walsh M, et al. AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2017, 102(9):3327-3339. doi: 10.1210/jc.2017-00947. doi: 10.1210/jc.2017-00947 URL
[35]	Traish A, Bolanos J, Nair S, et al. Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence[J]. J Clin Med, 2018, 7(12):549. doi: 10.3390/jcm7120549. doi: 10.3390/jcm7120549 URL
[36]	Moulana M. Immunophenotypic profile of leukocytes in hyperandrogenemic female rat an animal model of polycystic ovary syndrome[J]. Life Sci, 2019, 220:44-49. doi: 10.1016/j.lfs.2019. 01.048. doi: 10.1016/j.lfs.2019. 01.048 URL
[37]	Kakino S, Ohki T, Nakayama H, et al. Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model[J]. Horm Metab Res, 2018, 50(1):80-87. doi: 10.1055/s-0043-118666. doi: 10.1055/s-0043-118666 URL
[38]	Saklamaz A, Calan M, Yilmaz O, et al. Polycystic ovary syndrome is associated with increased osteopontin levels[J]. Eur J Endocrinol, 2016, 174(4):415-423. doi: 10.1530/EJE-15-1074. doi: 10.1530/EJE-15-1074 pmid: 26701868
[39]	Wang Y, Zhou W, Wu C, et al. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study[J]. Reprod Biol Endocrinol, 2018, 16(1):31. doi: 10.1186/s12958-018-0331-4. doi: 10.1186/s12958-018-0331-4 URL
[40]	Tang M, Jiang Y, Jia H, et al. Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease[J]. Artif Cells Nanomed Biotechnol, 2020, 48(1):159-168. doi: 10.1080/21691401. 2019.1699822. doi: 10.1080/21691401.2019.1699822 pmid: 31852298
[41]	Wu J, Wu D, Zhang L, et al. NK cells induce hepatic ER stress to promote insulin resistance in obesity through osteopontin production[J]. J Leukoc Biol, 2020, 107(4):589-596. doi: 10.1002/JLB.3MA1119-173R. doi: 10.1002/JLB.3MA1119-173R URL
[42]	Zhu C, Kim K, Wang X, et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis[J]. Sci Transl Med, 2018, 10(468):eaat0344. doi: 10.1126/scitranslmed.aat0344. doi: 10.1126/scitranslmed.aat0344
[43]	Arriazu E, Ge X, Leung TM, et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury[J]. Gut, 2017, 66(6):1123-1137. doi: 10.1136/gutjnl-2015-310752. doi: 10.1136/gutjnl-2015-310752 pmid: 26818617